Partnerships
NeoMatrix has received competitive funding from the Armed Forces Institute of Regenerative Medicine (AFIRM), the Joint Warfighter Medical Research Program (JWMRP), and the Military Burn Research Program (MBRP) to develop our novel medicine peptides. To date, NeoMatrix has received $20M in non-dilutive funding. As a result of this funding, NMT-cP12 is Phase 2a-ready and NMT-cNP8 has recently completed a Phase 1 clinical trial.
We are interested in exploring investments and/or strategic collaborations with pharma partners whose capability and expertise will supplement ours in advancing our products through the clinic and to the market.
About Our Award Funding
ACTIVE:
​
-
USAMRDC CDMRP | HT9425-23-9-0022 • 11/10/24 - 10/31/27
-
A Phase 2a Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of a Single Dose of cP12 in Otherwise Healthy Adults with Up To and Including 5% Total Body Surface Area Thermal Burns
-
​​
-
USAMRDC CDMRP | HT9425-23-1-1064 • 09/30/23 - 09/29/26
-
A Phase 1 Randomized, Placebo-Controlled, Single Ascending Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of cNP8 in Healthy Adults
-
​
-
USAMRDC CDMRP JWMRP | W81XWH-22-C-0005 • 09/03/22 - 09/02/25
-
NP8 delivered topically in a tyrosine-derived fiber mat to reduce burn injury progression, speed wound closure, and mitigate scarring
-
​
COMPLETE:
-
DMRDP | W81XWH-20-1-0874 • 10/01/20 - 09/31/23
-
IND-enabling Studies for Scalable Peptide Therapy to Limit Burn Conversion and Speed Wound Closure
-
​
-
USAMRDC MBRP | W81XWH-18-2-0059 • 09/30/18 - 09/30/22
-
A Phase 1 Randomized, Placebo-Controlled, Single Ascending Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of cP12 in Health Adults
-
​
-
USAMRDC MBRP | W81XWH-17-2-0062 • 09/01/17 - 03/31/22
-
Promote Faster and Scarless Healing of Burn Wounds by ArF Excimer Laser Debriding Burn Eschar, not Viable Skin​
-
​​​​
-
USAMRDC CDMRP JWMRP | W81XWH-15-C-0043 • 09/24/15 - 09/30/18
-
IND Filing for intravenous cP12 and pre-IND studies for topical cNP5 to limit burn injury progression​
-
The views expressed on this website are those of the author and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.